血液癌症治療：2030 年前的全球市場

2025 年全球血液癌症治療市場價值為 771 億美元，預計從 2025 年到 2030 年將以 10.2% 的複合年成長率成長，到 2030 年底達到 1255 億美元。

本報告範圍

本報告分析了血液癌症治療市場的趨勢，提供了2024年的數據、2025年的預測數據、2030年之前的複合年成長率預測（預測期：2025-2030年），以及區域市場細分資訊。該報告還涵蓋了市場潛力、競爭格局、監管趨勢、成長要素、限制因素和機遇，以及2030年的市場預測和主要參與者的市場佔有率。

本報告將市場按類型細分為白血病、淋巴瘤、多發性骨髓瘤和罕見血液系統疾病。白血病進一步細分為急性淋巴性白血病 (ALL)、慢性淋巴性白血病(CLL)、急性骨髓性白血病 (AML) 和慢性骨髓性白血病 (CML)。淋巴瘤進一步細分為非非何傑金氏淋巴瘤和何傑金氏淋巴瘤。罕見血液系統疾病包括骨髓發育不良症候群(MDS) 和骨髓增生性腫瘤 (MPN)。

該市場按主要區域分類，包括北美、歐洲、亞太、中東和非洲以及南美。各區域細分市場對美國、加拿大、墨西哥、德國、英國、英國、義大利、西班牙、日本、中國、韓國、澳洲和印度等主要國家進行了詳細分析。市場估算和預測以2024年為基準年，並對2025年和2030年進行了預測。

本報告的目的如下：

• 分析血液癌症治療藥物的類型。
• 分析全球市場規模和細分。
• 找出限制和刺激市場的因素。
• 提供至 2030 年的詳細市場預測。
• 評估市場佔有率、競爭優勢和產業結構。
• 我們將確定其對血液癌症治療市場的潛在長期影響。

本報告內容

• 數據表 88 和附加表 63
• 全球血液癌症治療市場概述與分析。
• 全球市場趨勢分析（包括 2024 年銷售數據、2025 年估計值以及到 2030 年的複合年成長率預測）
• 目前市場規模、估計和成長預測，以及按癌症類型、治療類型和地區分類的市場佔有率分析。
• 有關市場動態的事實和數據，包括主要市場促進因素、阻礙因素、挑戰和機會。
• 透過對宏觀經濟因素和波特五力分析的分析得出的見解
• 北美、歐洲和亞太地區監管環境概述
• 新興技術和發展趨勢的分析，包括臨床試驗、研發管線分析和專利趨勢。
• 依血液腫瘤類型（包括白血病、淋巴瘤和多發性骨髓瘤）進行詳細的市場分析。
• 區域市場分析涵蓋北美、歐洲、亞太地區、中東和非洲以及南美（包括特定國家的數據）。
• 分析競爭格局，包括企業市場占有率分析和策略舉措。
• 業界領導企業的公司簡介，包括強生公司、百時美施貴寶公司、艾伯維公司、諾華公司和羅氏公司。

目錄

第1章：執行摘要

第2章 市場概覽

• 概述
• 宏觀經濟因素分析
• 美國關稅對製藥業的影響
• 醫療保健支出
• 全球經濟成長（GDP）對製藥業的影響
• 波特五力分析
• 產業競爭力

第3章 市場動態

• 市場動態
• 市場促進因素
• 血液癌症病例數增加
• 血液癌症負擔日益加重
• 參與企業增加了研發投入
• 政府投入及製藥業研發支出增加
• 市場限制因素
• 學名藥競爭加劇和專利到期
• 價格低廉的化療藥物的普及限制了先進療法的發展。
• 血液癌症治療藥物高成本
• 市場機遇
• 具有治療血液癌症的潛力
• 新興市場
• 製藥生產技術進步

第4章 監管情勢

• 概述
• 美國
• 歐洲
• 亞太地區

第5章：新興技術與管道分析

• 概述
• 人工智慧（AI）
• 抗體修飾的奈米系統
• 標靶藥物遞送
• 臨床試驗分析
• 依研究類型進行臨床試驗分析
• 臨床試驗進展分析
• 分階段臨床試驗分析
• 專利分析

第6章 市場區隔分析

• 細分市場
• 全球血液癌症治療市場：依癌症類型分類
• 淋巴瘤
• 白血病
• 多發性骨髓瘤
• 罕見血液癌症
• 全球血液癌症治療市場：依治療類型分類
• 標靶治療
• 免疫療法
• 化療
• 按地區分類
• 全球血液癌症治療市場：按地區分類
• 北美洲
• 歐洲
• 亞太地區
• 中東和非洲
• 中東
• 南美洲

第7章 競爭情勢

• 競爭格局
• 企業市場占有率分析

第8章附錄

• 調查方法
• 簡稱
• 資訊來源
• 公司簡介
• ABBVIE INC.
• AMGEN INC.
• AMNEAL PHARMACEUTICALS LLC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC
• MERCK & CO. INC.
• NOVARTIS AG
• REGENERON PHARMACEUTICALS INC.
• SANOFI

The global market for blood cancer therapeutics was valued at $77.1 billion in 2025 and is projected to reach $125.5 billion by the end of 2030, at a compound annual growth rate (CAGR) of 10.2% from 2025 to 2030.

Report Scope

This report analyzes market trends for blood cancer therapeutics, providing data from 2024, 2025 estimates, compound annual growth rate projections through 2030 (forecast period: 2025-2030), and regional markets. It covers the market potential, competitive environment, regulatory scenarios, drivers, restraints, and opportunities, as well as market projections for 2030 and market share for key companies.

The market scope in this report is segmented by type into leukemia, lymphoma, multiple myeloma, and rare blood disorders. Leukemia is further subdivided into acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myelogenous (myeloid) leukemia (AML), and chronic myelogenous (myeloid) leukemia (CML). Lymphoma is further subdivided into non-Hodgkin lymphoma and Hodgkin lymphoma. Rare blood disorders include myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs).

The market has been segmented into significant geographies: North America, Europe, Asia-Pacific, the Middle East and Africa, and South America. The regional segment will provide a detailed analysis of major countries, including the U.S., Canada, Mexico, Germany, the U.K., France, Italy, Spain, Japan, China, South Korea, Australia, and India. For market estimates, data will be provided for 2024 as the base year, with forecasts for 2025 and a 2030 forecast value.

The report aims to:

• Analyze types of blood cancer therapeutics.
• Analyze global market size and segmentation.
• Understand market constraints and drivers.
• Provide detailed market forecasts for 2030.
• Assess market shares, competitiveness, and industry structure.
• Identify potential long-term impacts on the blood cancer therapeutics market.

Report Includes

• 88 data tables and 63 additional tables
• An overview and analysis of the global blood cancer therapeutics market
• Analyses of global market trends, with revenue data for 2024, estimates for 2025, and projections of CAGRs through 2030
• Estimates of the current market size and growth prospects, with a market share analysis by cancer type, therapeutic class, and region
• Facts and figures related to market dynamics, including key drivers, restraints, challenges, and opportunities
• Review of macroeconomic factors and insights derived from Porter's Five Forces analysis
• Overview of the regulatory landscape across North America, Europe, and Asia-Pacific
• Discussion of emerging technologies and developments, including clinical trials, pipeline analysis, and patent activity
• Detailed market analysis by blood cancer type, including leukemia, lymphoma, and multiple myeloma
• Regional market analysis covering North America, Europe, Asia-Pacific, the Middle East and Africa, and South America, with country-level data
• Analysis of the competitive landscape, including company share analysis and strategic initiatives
• Company profiles of major players within the industry, including Johnson & Johnson, Bristol-Myers Squibb Co., AbbVie Inc., Novartis AG, and F. Hoffmann-La Roche Ltd.

Table of Contents

Chapter 1 Executive Summary

• Market Outlook
• Scope of Report
• Market Summary
• Market Dynamics and Growth Factors
• Emerging Technologies
• Segmental Analysis
• Regional Analysis
• Conclusion

Chapter 2 Market Overview

• Overview
• Macroeconomic Factor Analysis
• Impact of U.S. Tariffs on the Pharmaceutical Industry
• Healthcare Expenditure
• Impact of Global Economic Growth (GDP) on the Pharma Sector
• Porter's Five Forces Analysis
• Bargaining Power of Buyers
• Bargaining Power of Suppliers
• Potential for New Entrants
• Threat of Substitutes
• Competitiveness in the Industry

Chapter 3 Market Dynamics

• Market Dynamics
• Market Drivers
• Rise in Blood Cancer Cases
• Increasing Burden of Blood Cancers
• Rising R&D Investment Among Companies in the Market
• Increase in Government Funding and Pharmaceutical R&D Expenditures
• Market Restraints
• Rising Generic Competition and Patent Expiration
• Availability of Affordable Chemotherapeutics Restricts Growth of Advanced Therapies
• High Cost of Blood Cancer Therapeutics
• Market Opportunities
• Potential of Blood Cancer Therapeutics
• Emerging Markets
• Technological Advances in Drug Manufacturing

Chapter 4 Regulatory Landscape

• Overview
• U.S.
• Europe
• Asia-Pacific

Chapter 5 Emerging Technologies and Pipeline Analysis

• Overview
• Artificial Intelligence (AI)
• Antibody-Modified Nanosystems
• Targeted Drug Delivery
• Clinical Trial Analysis
• Clinical Trials Analysis by Type of Study
• Clinical Trials Analysis by Status
• Clinical Trials Analysis by Phase
• Key Takeaways
• Patent Analysis
• Key Takeaways

Chapter 6 Market Segmentation Analysis

• Segmentation Breakdown
• Global Market for Blood Cancer Therapeutics, by Cancer Type
• Key Takeaways
• Lymphoma
• Leukemia
• Multiple Myeloma
• Rare Blood Cancers
• Global Market for Blood Cancer Therapeutics, by Therapeutic Type
• Key Takeaways
• Targeted Therapy
• Immunotherapy
• Chemotherapy
• Geographic Breakdown
• Global Market for Blood Cancer Therapeutics, by Region
• Key Takeaways
• North America
• Europe
• Asia-Pacific
• Middle East and Africa
• Middle East
• South America

Chapter 7 Competitive Intelligence

• Key Takeaways
• Competitive Landscape
• Company Share Analysis

Chapter 8 Appendix

• Methodology
• Abbreviations
• Sources
• Company Profiles
• ABBVIE INC.
• AMGEN INC.
• AMNEAL PHARMACEUTICALS LLC.
• ASTRAZENECA
• BRISTOL-MYERS SQUIBB CO.
• F. HOFFMANN-LA ROCHE LTD.
• GILEAD SCIENCES INC.
• GSK PLC.
• JAZZ PHARMACEUTICALS INC.
• JOHNSON & JOHNSON
• LILLY USA LLC
• MERCK & CO. INC.
• NOVARTIS AG
• REGENERON PHARMACEUTICALS INC.
• SANOFI

List of Tables

• Summary Table : Global Market for Blood Cancer Therapeutics, by Region, Through 2030
• Table 1 : Current Health Expenditure, by Country, 2021-2023
• Table 2 : Projected Leukemia Cases, by Region, Through 2035
• Table 3 : Projected Hodgkin Lymphoma Cases, by Region, Through 2035
• Table 4 : Projected Non-Hodgkin Lymphoma Cases, by Region, Through 2035
• Table 5 : Projected Multiple Myeloma Cases, by Region, Through 2035
• Table 6 : National Cancer Institute Funding, by Mechanism, 2020-2024
• Table 7 : Few Approved Biosimilars in the Market for Blood Cancer
• Table 8 : Average Price of a Blood Cancer Therapeutic
• Table 9 : Clinical Trials in Blood Cancer Therapeutics, by Type of Study, as of January 2026
• Table 10 : Clinical Trials in Blood Cancer Therapeutics, by Status, as of January 2026
• Table 11 : Clinical Trials in Blood Cancer Therapeutics, by Phase, as of January 2026
• Table 12 : List of Selected Blood Cancer Clinical Trials in Phase IV
• Table 13 : List of Selected Recent Patents Related to Blood Cancer, 2026
• Table 14 : Global Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 15 : Subtypes of Non-Hodgkin Lymphoma, by Type
• Table 16 : Subtypes of Hodgkin Lymphoma, by Type
• Table 17 : Global Market for Lymphoma in Blood Cancer Therapeutics, by Type, Through 2030
• Table 18 : Global Market for Lymphoma in Blood Cancer Therapeutics, by Region, Through 2030
• Table 19 : Global Market for Leukemia in Blood Cancer Therapeutics, by Type, Through 2030
• Table 20 : Global Market for Leukemia in Blood Cancer Therapeutics, by Region, Through 2030
• Table 21 : Global Market for Multiple Myeloma in Blood Cancer Therapeutics, by Region, Through 2030
• Table 22 : Global Market for Rare Blood Cancers in Blood Cancer Therapeutics, by Region, Through 2030
• Table 23 : Global Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 24 : Few Approved Targeted Therapies in the Blood Cancer Therapeutics Market
• Table 25 : Global Market for Targeted Therapy in Blood Cancer Therapeutics, by Region, Through 2030
• Table 26 : Few Approved Immunotherapies in the Blood Cancer Therapeutics Market
• Table 27 : Global Market for Immunotherapy in Blood Cancer Therapeutics, by Region, Through 2030
• Table 28 : Approved Chemotherapies in the Blood Cancer Therapeutics Market
• Table 29 : Global Market for Chemotherapy in Blood Cancer Therapeutics, by Region, Through 2030
• Table 30 : Global Market for Blood Cancer Therapeutics, by Region, Through 2030
• Table 31 : North American Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 32 : North American Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 33 : North American Market for Blood Cancer Therapeutics, by Country, Through 2030
• Table 34 : Projected Number of New Blood Cancer Cases and Deaths by Sex in the U.S., 2026
• Table 35 : U.S. Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 36 : U.S. Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 37 : Canadian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 38 : Canadian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 39 : Mexican Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 40 : Mexican Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 41 : European Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 42 : European Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 43 : European Market for Blood Cancer Therapeutics, by Country, Through 2030
• Table 44 : German Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 45 : German Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 46 : U.K. Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 47 : U.K. Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 48 : French Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 49 : French Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 50 : Italian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 51 : Italian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 52 : Spanish Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 53 : Spanish Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 54 : Rest of Europe Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 55 : Rest of Europe Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 56 : Asia-Pacific Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 57 : Asia-Pacific Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 58 : Asia-Pacific Market for Blood Cancer Therapeutics, by Country, Through 2030
• Table 59 : Japanese Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 60 : Japanese Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 61 : Chinese Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 62 : Chinese Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 63 : Indian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 64 : Indian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 65 : South Korean Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 66 : South Korean Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 67 : Australian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 68 : Australian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 69 : Rest of Asia-Pacific Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 70 : Rest of Asia-Pacific Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 71 : Middle East and African Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 72 : Middle East and African Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 73 : Middle East and African Market for Blood Cancer Therapeutics, by Region, Through 2030
• Table 74 : Middle East Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 75 : Middle East Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 76 : African Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 77 : African Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 78 : South American Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 79 : South American Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 80 : South American Market for Blood Cancer Therapeutics, by Country, Through 2030
• Table 81 : Brazilian Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 82 : Brazilian Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 83 : Argentine Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 84 : Argentine Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 85 : Rest of South America Market for Blood Cancer Therapeutics, by Cancer Type, Through 2030
• Table 86 : Rest of South America Market for Blood Cancer Therapeutics, by Therapy Type, Through 2030
• Table 87 : Key Strategic Initiatives, 2024-2026
• Table 88 : Abbreviations Used in this Report
• Table 89 : Report Sources
• Table 90 : AbbVie Inc.: Company Snapshot
• Table 91 : AbbVie Inc.: Financial Performance, FY 2023 and 2024
• Table 92 : AbbVie Inc.: Product Portfolio
• Table 93 : AbbVie Inc.: News/Key Developments, 2023-2025
• Table 94 : Amgen Inc.: Company Snapshot
• Table 95 : Amgen Inc.: Financial Performance, FY 2023 and 2024
• Table 96 : Amgen Inc.: Product Portfolio
• Table 97 : Amgen Inc.: News/Key Developments, 2022-2026
• Table 98 : Amneal Pharmaceuticals LLC.: Company Snapshot
• Table 99 : Amneal Pharmaceuticals LLC.: Financial Performance, FY 2023 and 2024
• Table 100 : Amneal Pharmaceuticals LLC.: Product Portfolio
• Table 101 : Amneal Pharmaceuticals LLC.: News/Key Developments, 2025
• Table 102 : AstraZeneca: Company Snapshot
• Table 103 : AstraZeneca: Financial Performance, FY 2023 and 2024
• Table 104 : AstraZeneca: Product Portfolio
• Table 105 : AstraZeneca: News/Recent Developments, 2023-2025
• Table 106 : Bristol-Myers Squibb Co.: Company Snapshot
• Table 107 : Bristol-Myers Squibb Co.: Financial Performance, FY 2023 and 2024
• Table 108 : Bristol-Myers Squibb Co.: Product Portfolio
• Table 109 : Bristol-Myers Squibb Co.: News/Key Developments, 2023-2026
• Table 110 : F. Hoffmann-La Roche Ltd.: Company Snapshot
• Table 111 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2023 and 2024
• Table 112 : F. Hoffmann-La Roche Ltd.: Product Portfolio
• Table 113 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2023-2025
• Table 114 : Gilead Sciences Inc.: Company Snapshot
• Table 115 : Gilead Sciences Inc.: Financial Performance, FY 2023 and 2024
• Table 116 : Gilead Sciences Inc.: Product Portfolio
• Table 117 : Gilead Sciences Inc.: News/Key Developments, 2023-2025
• Table 118 : GSK plc: Company Snapshot
• Table 119 : GSK plc: Financial Performance, FY 2023 and 2024
• Table 120 : GSK plc: Product Portfolio
• Table 121 : GSK plc: News/Key Developments, 2025
• Table 122 : Jazz Pharmaceuticals Inc.: Company Snapshot
• Table 123 : Jazz Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 124 : Jazz Pharmaceuticals Inc.: Product Portfolio
• Table 125 : Jazz Pharmaceuticals Inc.: News/Key Developments, 2023
• Table 126 : Johnson & Johnson: Company Snapshot
• Table 127 : Johnson & Johnson: Financial Performance, FY 2023 and 2024
• Table 128 : Johnson & Johnson: Product Portfolio
• Table 129 : Johnson & Johnson: News/Key Developments, 2024-2026
• Table 130 : Lilly USA LLC: Company Snapshot
• Table 131 : Lilly USA LLC: Financial Performance, FY 2023 and 2024
• Table 132 : Lilly USA LLC: Product Portfolio
• Table 133 : Lilly USA LLC: News/Key Development, 2023-2025
• Table 134 : Merck & Co. Inc.: Company Snapshot
• Table 135 : Merck & Co. Inc.: Financial Performance, FY 2023 and 2024
• Table 136 : Merck & Co. Inc.: Product Portfolio
• Table 137 : Merck & Co. Inc.: News/Key Developments, 2025
• Table 138 : Novartis AG: Company Snapshot
• Table 139 : Novartis AG: Financial Performance, FY 2023 and 2024
• Table 140 : Novartis AG: Product Portfolio
• Table 141 : Novartis AG: News/Key Developments, 2022-2024
• Table 142 : Regeneron Pharmaceuticals Inc.: Company Snapshot
• Table 143 : Regeneron Pharmaceuticals Inc.: Financial Performance, FY 2023 and 2024
• Table 144 : Regeneron Pharmaceuticals Inc.: Product Portfolio
• Table 145 : Regeneron Pharmaceuticals Inc.: News/Key Developments, 2022-2025
• Table 146 : Sanofi: Company Snapshot
• Table 147 : Sanofi: Financial Performance, FY 2023 and 2024
• Table 148 : Sanofi: Product Portfolio
• Table 149 : Sanofi: News/Key Developments, 2022-2025
• Table 150 : Few Emerging Companies in the Blood Cancer Therapeutics Market

List of Figures

• Summary Figure : Global Market Shares of Blood Cancer Therapeutics, by Region, 2024
• Figure 1 : Porter's Five Forces Analysis of the Blood Cancer Therapeutics Market
• Figure 2 : Market Dynamics of Blood Cancer Therapeutics
• Figure 3 : Companies' Expenditure, by Function, 2022
• Figure 4 : Global Pharmaceutical R&D Spending and Growth, 2020-2026
• Figure 5 : Global Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 6 : Global Market Shares of Lymphoma in Blood Cancer Therapeutics, by Region, 2024
• Figure 7 : Global Market Shares of Leukemia in Blood Cancer Therapeutics, by Region, 2024
• Figure 8 : Global Market Shares of Multiple Myeloma in Blood Cancer Therapeutics, by Region, 2024
• Figure 9 : Global Market Shares of Rare Blood Cancers in Blood Cancer Therapeutics, by Region, 2024
• Figure 10 : Global Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 11 : Global Market Shares of Targeted Therapy in Blood Cancer Therapeutics, by Region, 2024
• Figure 12 : Global Market Shares of Immunotherapy in Blood Cancer Therapeutics, by Region, 2024
• Figure 13 : Global Market Shares of Chemotherapy in Blood Cancer Therapeutics, by Region, 2024
• Figure 14 : Global Market Shares of Blood Cancer Therapeutics, by Region, 2024
• Figure 15 : North American Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 16 : North American Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 17 : North American Market Shares of Blood Cancer Therapeutics, by Country, 2024
• Figure 18 : U.S. Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 19 : U.S. Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 20 : Canadian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 21 : Canadian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 22 : Mexican Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 23 : Mexican Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 24 : European Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 25 : European Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 26 : European Market Shares of Blood Cancer Therapeutics, by Country, 2024
• Figure 27 : German Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 28 : German Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 29 : U.K. Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 30 : U.K. Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 31 : French Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 32 : French Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 33 : Italian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 34 : Italian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 35 : Spanish Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 36 : Spanish Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 37 : Rest of Europe Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 38 : Rest of Europe Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 39 : Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 40 : Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 41 : Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Country, 2024
• Figure 42 : Japanese Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 43 : Japanese Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 44 : Chinese Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 45 : Chinese Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 46 : Indian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 47 : Indian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 48 : South Korean Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 49 : South Korean Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 50 : Australian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 51 : Australian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 52 : Rest of Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 53 : Rest of Asia-Pacific Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 54 : Middle East and African Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 55 : Middle East and African Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 56 : Middle East and African Market Shares of Blood Cancer Therapeutics, by Region, 2024
• Figure 57 : Middle East Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 58 : Middle East Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 59 : African Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 60 : African Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 61 : South American Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 62 : South American Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 63 : South American Market Shares of Blood Cancer Therapeutics, by Country, 2024
• Figure 64 : Brazilian Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 65 : Brazilian Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 66 : Argentine Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 67 : Argentine Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 68 : Rest of South America Market Shares of Blood Cancer Therapeutics, by Cancer Type, 2024
• Figure 69 : Rest of South America Market Shares of Blood Cancer Therapeutics, by Therapy Type, 2024
• Figure 70 : Global Market Shares for Blood Cancer Therapeutics, by Company, 2024
• Figure 71 : AbbVie Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 72 : AbbVie Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 73 : Amgen Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 74 : Amgen Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 75 : Amneal Pharmaceuticals LLC.: Revenue Share, by Business Unit, FY 2024
• Figure 76 : AstraZeneca: Revenue Share, by Business Unit, FY 2024
• Figure 77 : AstraZeneca: Revenue Share, by Country/Region, FY 2024
• Figure 78 : Bristol-Myers Squibb Co.: Revenue Share, by Business Unit, FY 2024
• Figure 79 : Bristol-Myers Squibb Co.: Revenue Share, by Country/Region, FY 2024
• Figure 80 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Business Unit, FY 2024
• Figure 81 : F. Hoffmann-La Roche Ltd.: Revenue Share, by Country/Region, FY 2024
• Figure 82 : Gilead Sciences Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 83 : Gilead Sciences Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 84 : GSK plc: Revenue Share, by Business Unit, FY 2024
• Figure 85 : GSK plc: Revenue Share, by Country/Region, FY 2024
• Figure 86 : Jazz Pharmaceuticals Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 87 : Jazz Pharmaceuticals Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 88 : Johnson & Johnson: Revenue Share, by Business Unit, FY 2024
• Figure 89 : Johnson & Johnson: Revenue Share, by Country/Region, FY 2024
• Figure 90 : Lilly USA LLC: Revenue Shares, by Business Unit, FY 2024
• Figure 91 : Lilly USA LLC: Revenue Shares, by Country/Region, FY 2024
• Figure 92 : Merck & Co. Inc.: Revenue Share, by Business Unit, FY 2024
• Figure 93 : Merck & Co. Inc.: Revenue Share, by Country/Region, FY 2024
• Figure 94 : Novartis AG: Revenue Shares, by Business Unit, FY 2024
• Figure 95 : Novartis AG: Revenue Shares, by Country/Region, FY 2024
• Figure 96 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Business Unit, FY 2024
• Figure 97 : Regeneron Pharmaceuticals Inc.: Revenue Shares, by Country/Region, FY 2023
• Figure 98 : Sanofi: Revenue Share, by Country/Region, FY 2024